Quality of Medication Treatment for Opioid Use Disorder in Medicaid-enrollees: The Effects of State Policies and Intiatives

医疗补助参与者阿片类药物使用障碍的药物治疗质量：国家政策和举措的影响

基本信息

批准号：
10392358
负责人：
BRADLEY D STEIN
金额：
$ 25.52万
依托单位：
RAND CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-07-01 至 2024-10-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10392358
关键词：
Address Affect Attention Buprenorphine Caring Characteristics Clinical Communities Counseling County Data Disadvantaged Drug usage Effectiveness Health Health Benefit Health Services Accessibility Individual Injectable Insurance Interview Laboratories Medicaid Medical Methadone Monitor Naltrexone National Institute of Drug Abuse Outcome Patients Performance Pharmaceutical Preparations Policies Population Pregnant Women Provider Public Health Quality of Care Research Resources Role Services Site Visit Structure Time Variant care costs comorbidity cost deviant dosage effective intervention ethnic minority federal policy health care disparity heroin use high risk population improved improved outcome informant opioid overdose opioid treatment program opioid use disorder parity prescription opioid misuse prior authorization racial and ethnic rural counties screening substance abuse treatment treatment duration waiver

项目摘要

Project Summary Opioid use disorders are a significant public health crisis, and medication treatment is the most effective intervention for individuals with opioid use disorder. State policies and initiatives have increased medication treatment utilization over the last decade, but increased utilization without attention to quality of care might limit the public health benefits of medication treatment. Many states have begun implementing policies and initiatives to improve quality, although with little empirical support of their effectiveness in real world settings. This project will characterize how quality care for Medicaid-enrollees receiving medication treatment for opioid use disorder and related health outcomes have changed over time, overall, and among historically underserved and high-risk populations. We will then examine the extent to which policies and initiatives that increase access and those aimed at improving quality are associated with better quality of care and related health outcomes, overall, and for historically underserved and high-risk populations

项目概要阿片类药物使用障碍是一个重大的公共卫生危机，药物治疗是最有效的对阿片类药物使用障碍患者的干预。国家政策和举措加大了用药力度过去十年的治疗利用率，但在不关注护理质量的情况下增加利用率可能会限制药物治疗的公共健康益处。不少州已开始落实相关政策提高质量的举措，尽管在现实世界中很少有实证支持其有效性。该项目将描述如何为接受阿片类药物治疗的医疗补助参与者提供优质护理使用障碍和相关的健康结果随着时间的推移，总体上以及历史上发生了变化服务不足和高风险人群。然后我们将研究政策和举措在多大程度上增加获取机会和旨在提高质量的那些措施与更好的护理质量和相关总体健康结果以及历史上服务不足和高风险人群的健康结果

项目成果

期刊论文数量（36）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Growing racial/ethnic disparities in buprenorphine distribution in the United States, 2007-2017.

2007-2017 年美国丁丙诺啡分布的种族/民族差异日益扩大。

DOI：
发表时间：
2021
期刊：
影响因子：
4.2
作者：
Schuler, Megan S;Dick, Andrew W;Stein, Bradley D
通讯作者：
Stein, Bradley D

Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic.

在 COVID-19 大流行的初始阶段，为那些拥有雇主赞助保险的人使用丁丙诺啡。

DOI：
发表时间：
2021-10
期刊：
影响因子：
3.9
作者：
Cantor, Jonathan;Dick, Andrew W;Haffajee, Rebecca;Pera, Megan F;Bravata, Dena M;Stein, Bradley D;Whaley, Christopher M
通讯作者：
Whaley, Christopher M

Postpartum Treatment for Substance Use Disorder Among Mothers of Infants with Neonatal Abstinence Syndrome and Prenatal Substance Exposure.

患有新生儿戒断综合症和产前药物暴露的婴儿母亲的药物使用障碍的产后治疗。